Comparison of loss of response between anti-tumor necrosis factor alone and combined use with immunomodulators in patients with inflammatory bowel disease

BACKGROUND/AIMS: Combination therapy with immunomodulators (IMMs) was proposed as a strategy to prevent the development of loss of response (LOR) to anti-tumor necrosis factor (TNF) for patients with inflammatory bowel disease (IBD). However, the effect is unclear in patients already exposed to IMMs...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Seung Wook, Park, Jaewoo, Yoon, Hyuk, Yang, Hye Ran, Shin, Cheol Min, Park, Young Soo, Kim, Nayoung, Lee, Dong Ho, Kim, Joo Sung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association of Internal Medicine 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8009168/
https://www.ncbi.nlm.nih.gov/pubmed/32580540
http://dx.doi.org/10.3904/kjim.2019.279

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8009168/
https://www.ncbi.nlm.nih.gov/pubmed/32580540
http://dx.doi.org/10.3904/kjim.2019.279

Ejemplares similares